Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
Solventum Corporation (NYSE: SOLV ) is one of the cheap new stocks to buy now . On February 26, Solventum reported Q4 2025 financial results that exceeded expectations, despite a reported sales decline of 3.7% to $2 billion. This decrease was driven by the divestiture of the company's Purification and Filtration business in September 2025. However, organic sales grew by 3.5%. The company achieved GAAP diluted EPS of $0.36 and adjusted diluted EPS of $1.57, fueled by debt reduction following the recent divestiture and operational efficiencies that helped offset incremental tariff headwinds. The MedSurg segment, Solventum's largest, led the growth with a 6.2% reported increase in Infection Prevention and Surgical Solutions. Dental Solutions also showed strong momentum with an 8.6% reported sales increase, while Health Information Systems grew by 3.7%. However, the company's free cash flow for the quarter was $33 million, a drop from the prior year's $92 million, reflecting the costs
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements [Yahoo! Finance]Yahoo! Finance
- Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript [Seeking Alpha]Seeking Alpha
- Esperion Therapeutics (ESPR) had its price target raised by Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)Business Wire
ESPR
Earnings
- 11/6/25 - Miss
ESPR
Sec Filings
- 3/3/26 - Form 8-K
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- ESPR's page on the SEC website